Visiox Pharmaceuticals entered into a definitive merger agreement with Ocuvex Therapeutics, an ophthalmic pharmaceutical company that has a robust pipeline of near-term ophthalmic medicines. The strategic combination is set to position the newly combined entity as an emerging leader in the eye-care sector with a portfolio of ophthalmic medicines, Visiox said in a press release.

Visiox's products, including OMLONTI (omidenepag isopropyl ophthalmic solution), PDP-716 (brimonidine) 0.35% and SDN-037 (difluprednate) 0.04%, will grow Ocuvex's market presence and accelerate the commercialization of these promising therapeutics, Visiox said.

Going forward, the company will operate under the Ocuvex name, building on Visiox's commitment to disrupting the ophthalmic market through high-level collaboration with eye-care professionals.

"The combination of Visiox and Ocuvex makes for a perfect match," said Ryan S. Bleeks, chief executive officer of Visiox. "We have reached significant milestones with our products, and Ocuvex is in a great position to take these advancements forward and bring them to market faster and emerge as a future leader in eye care."